Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Crohn's disease

Fistulising disease—a problem shared is a problem halved?

Nature Reviews Gastroenterology & Hepatology volume 11, pages 581–583 (2014)Cite this article

Subjects

An international consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease has recently been published. The statement is an important starting point to address the many problems we still have with the clinical classification and treatment of fistulising Crohn's disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gecse, K. B. et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut http:/dx.doi.org/10.1136/gutjnl-2013-306709.

  2. Pittet, V. et al. Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Aliment. Pharmacol. Ther. 32, 1007–1016 (2010).

    Article  CAS  Google Scholar 

  3. Vermeire, S., Van Assche, G. & Rutgeerts, P. Perianal Crohn's disease: classification and clinical evaluation. Dig. Liver Dis. 39, 959–962 (2007).

    Article  CAS  Google Scholar 

  4. Irvine, E. J. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J. Clin. Gastroenterol. 20, 27–32 (1995).

    Article  CAS  Google Scholar 

  5. Present, D. H. et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398–1405 (1999).

    Article  CAS  Google Scholar 

  6. Schwartz, D. A. & Herdman, C. R. Review article: The medical treatment of Crohn's perianal fistulas. Aliment. Pharmacol. Ther. 19, 953–967 (2004).

    Article  CAS  Google Scholar 

  7. Van Assche, G. et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am. J. Gastroenterol. 98, 332–339 (2003).

    Article  Google Scholar 

  8. Bataille, F. et al. Morphological characterisation of Crohn's disease fistulae. Gut 53, 1314–1321 (2004).

    Article  CAS  Google Scholar 

  9. Bataille, F. et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm. Bowel Dis. 14, 1514–1527 (2008).

    Article  Google Scholar 

  10. Scharl, M. et al. Interleukin-13 and transforming growth factor β synergise in the pathogenesis of human intestinal fistulae. Gut 62, 63–72 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

G.R. acknowledges grant support from the Swiss National foundation (314730_153380 TDAG8, 324730_138291, 310030_138410 and 33CS30_148422, Swiss IBD Cohort study).

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University Hospital Zürich, Rämistrasse 100, Zürich, 8091, Switzerland

    Gerhard Rogler

Authors
  1. Gerhard Rogler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerhard Rogler.

Ethics declarations

Competing interests

G.R. has acted as a consultant to Abbott, Augurix, Calypso, Essex/MSD, FALK, Genentech, Novartis, Roche, Tillotts Pharma, UCB and Vifor Pharma. G.R. has received speaker's honoraria from Abbott, FALK, MSD, Phadia, Tillotts Pharma, UCB and Vifor Pharma, and received educational grants and research grants from Abbott, Ardeypharm, Essex/MSD, FALK, Flamentera AG, Novartis, Roche, Tillotts Pharma, UCB and Zeller.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rogler, G. Fistulising disease—a problem shared is a problem halved?. Nat Rev Gastroenterol Hepatol 11, 581–583 (2014). https://doi.org/10.1038/nrgastro.2014.142

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.142

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing